New Long-Read Genetic Test Enables Faster and More Comprehensive Diagnosis of Rare Diseases
November 18, 2025
Brand Name :
Spara, Zagam
Synonyms :
sparfloxacin
Class :
Quinolones
Dosage Forms & StrengthsÂ
TabletÂ
100mgÂ
200mgÂ
300mgÂ
100 to 300 mg orally daily, as a single or two divided doses
Dose Adjustments
Dosing modifications
Renal impairment:
Dose adjustment is required in case of severe impairment
Safety and efficacy were not establishedÂ
Refer to the adult dosing regimenÂ
magnesium Salts may decrease the serum concentration of quinolones
magnesium Salts may decrease the serum concentration of quinolones
magnesium Salts may decrease the serum concentration of quinolones
magnesium Salts may decrease the serum concentration of quinolones
magnesium Salts may decrease the serum concentration of quinolones
may enhance the anticoagulant effect of Vitamin K antagonists
may enhance the anticoagulant effect of Vitamin K antagonists
may enhance the anticoagulant effect of Vitamin K antagonists
may enhance the anticoagulant effect of Vitamin K antagonists
may enhance the anticoagulant effect of Vitamin K antagonists
may have a decreased serum concentration when combined with quinolones
may have a decreased serum concentration when combined with quinolones
may have a decreased serum concentration when combined with quinolones
may have a decreased serum concentration when combined with quinolones
may have a decreased serum concentration when combined with quinolones
may diminish the absorption when combined with quinolones
may diminish the absorption when combined with quinolones
may diminish the absorption when combined with quinolones
may diminish the absorption when combined with quinolones
may diminish the absorption when combined with quinolones
may enhance the QTc-prolonging effect of each other when combined
may enhance the QTc-prolonging effect of each other when combined
may enhance the QTc-prolonging effect of each other when combined
may enhance the QTc-prolonging effect of each other when combined
may enhance the QTc-prolonging effect of each other when combined
iron Preparations may decrease the serum concentration of quinolones
lanthanum may decrease the serum concentration of quinolones
may decrease the serum concentration of Quinolones
may decrease the serum concentration of Quinolones
may decrease the serum concentration of Quinolones
may decrease the serum concentration of Quinolones
may decrease the serum concentration of Quinolones
sevelamer may decrease the absorption of Quinolones
antacids may reduce the absorption of quinolones
antacids may reduce the absorption of quinolones
antacids may reduce the absorption of quinolones
antacids may reduce the absorption of quinolones
antacids may reduce the absorption of quinolones
may diminish the serum concentration of iron preparations
may decrease the serum concentration and decrease in the efficacy
may diminish the serum concentration when combined with quinolones
may diminish the serum concentration of magnesium salts
may reduce the level of serum concentration of quinolones
may reduce the level of serum concentration of quinolones
may reduce the level of serum concentration of quinolones
may reduce the level of serum concentration of quinolones
may reduce the level of serum concentration of quinolones
may diminish the absorption when combined with quinolones
may diminish the absorption when combined with quinolones
may diminish the absorption when combined with quinolones
may diminish the absorption when combined with quinolones
may diminish the absorption when combined with quinolones
may have an increased qtc-prolonging effect when combined with delamanid
may diminish the serum concentration when combined with didanosine
may diminish the serum concentration when combined with quinolones
l-methylfolate-pyridoxal 5′-phosphate-methylcobalamine
may diminish the serum concentration when combined with quinolones
may diminish the absorption when combined with quinolones
may diminish the serum concentration when combined with quinolones
may diminish the serum concentration when combined with quinolones
may diminish the absorption of Antacids
aluminum hydroxide/magnesium carbonateÂ
may decrease the bioavailability of antacids
may enhance the QTc-prolonging effect of each other when combined
calcium salts: they may diminish the absorption of quinolones
calcium salts: they may diminish the absorption of quinolones
calcium salts: they may diminish the absorption of quinolones
calcium salts: they may diminish the absorption of quinolones
may diminish the absorption when combined with quinolones
may diminish the absorption when combined with quinolones
sparfloxacin: they may increase the QTc-prolonging effect of QTc-prolonging Agents
sparfloxacin: they may increase the QTc-prolonging effect of QTc-prolonging Agents
sparfloxacin: they may increase the QTc-prolonging effect of QTc-prolonging Agents
sparfloxacin: they may increase the QTc-prolonging effect of QTc-prolonging Agents
sparfloxacin: they may increase the QTc-prolonging effect of QTc-prolonging Agents
may diminish the serum concentration of magnesium salts
may diminish the serum concentration when combined with quinolones
May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects
May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects
May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects
May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects
May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects
may have an increased anticoagulant effect when combined with vitamin k antagonists
may have an increased anticoagulant effect when combined with vitamin k antagonists
may have an increased anticoagulant effect when combined with vitamin k antagonists
may have an increased anticoagulant effect when combined with vitamin k antagonists
may have an increased anticoagulant effect when combined with vitamin k antagonists
quinolones: they may increase the hypoglycemic effect of agents with blood viscosity reducing agents
quinolones: they may increase the hypoglycemic effect of agents with blood viscosity reducing agents
it may diminish the excretion rate when combined with quinolones, resulting in an enhanced serum level
it may diminish the excretion rate when combined with quinolones, resulting in an enhanced serum level
it may diminish the excretion rate when combined with quinolones, resulting in an enhanced serum level
it may diminish the excretion rate when combined with quinolones, resulting in an enhanced serum level
it may diminish the excretion rate when combined with quinolones, resulting in an enhanced serum level
amphetamines may enhance the cardiotoxic effect of quinolones
amphetamines may enhance the cardiotoxic effect of quinolones
amphetamines may enhance the cardiotoxic effect of quinolones
antacids may decrease the absorption of quinolones
antacids may decrease the absorption of quinolones
antacids may decrease the absorption of quinolones
antacids may decrease the absorption of quinolones
antacids may decrease the absorption of quinolones
corticosteroids May enhance the adverse/toxic effect of quinolones.
corticosteroids May enhance the adverse/toxic effect of quinolones.
corticosteroids May enhance the adverse/toxic effect of quinolones.
corticosteroids May enhance the adverse/toxic effect of quinolones.
corticosteroids May enhance the adverse/toxic effect of quinolones.
NSAIDS may enhance the neuroexcitatory and/or seizure-potentiating effect of quinolones
NSAIDS may enhance the neuroexcitatory and/or seizure-potentiating effect of quinolones
NSAIDS may enhance the neuroexcitatory and/or seizure-potentiating effect of quinolones
NSAIDS may enhance the neuroexcitatory and/or seizure-potentiating effect of quinolones
NSAIDS may enhance the neuroexcitatory and/or seizure-potentiating effect of quinolones
quinolones may enhance the anticoagulant effect of Vitamin K antagonists
QT-prolonging Miscellaneous Agents may enhance the QTc-prolonging effect of Quinolone antibiotics
QT-prolonging Miscellaneous Agents may enhance the QTc-prolonging effect of Quinolone antibiotics
QT-prolonging Miscellaneous Agents may enhance the QTc-prolonging effect of Quinolone antibiotics
QT-prolonging Miscellaneous Agents may enhance the QTc-prolonging effect of Quinolone antibiotics
QT-prolonging Miscellaneous Agents may enhance the QTc-prolonging effect of Quinolone antibiotics
may increase the hypoglycaemic effect
may increase the hypoglycaemic effect
may increase the hypoglycaemic effect
may increase the hypoglycaemic effect
may increase the hypoglycaemic effect
may increase the toxic effect of corticosteroids
may increase the hypotensive effect of antihypertensives
may enhance the adverse effect of quinolones
may enhance the adverse effect of quinolones
may enhance the adverse effect of quinolones
may enhance the adverse effect of quinolones
may enhance the adverse effect of quinolones
may enhance the adverse effect of quinolones
may enhance the adverse effect of quinolones
may enhance the adverse effect of quinolones
may enhance the adverse effect of quinolones
may enhance the adverse effect of quinolones
may enhance the adverse effect of quinolones
may enhance the adverse effect of quinolones
may enhance the adverse effect of quinolones
may increase the hypoglycemic effect of blood glucose-lowering agents
may increase the QTc prolonging effect of QTc prolonging agents
may have an increased cardiotoxic effect when combined with quinolones
may have an increased cardiotoxic effect when combined with quinolones
may diminish the serum concentration when combined with mycophenolate
may have an increased neuroexcitatory and/or seizure-potentiating effect when combined with quinolones
may have an increased neuroexcitatory and/or seizure-potentiating effect when combined with quinolones
may have an increased neuroexcitatory and/or seizure-potentiating effect when combined with quinolones
may have an increased neuroexcitatory and/or seizure-potentiating effect when combined with quinolones
may have an increased neuroexcitatory and/or seizure-potentiating effect when combined with quinolones
may diminish the excretion when combined with quinolones
may enhance the toxic effect of quinolones
may enhance the toxic effect of quinolones
may enhance the toxic effect of quinolones
may enhance the toxic effect of quinolones
may enhance the toxic effect of quinolones
may increase the hypoglycemic effect of Agents with Blood Glucose Lowering Effects
may increase the Glucose-lowering effect of Agents with Blood Glucose Lowering Effects
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may have an increased hypoglycemic effect when combined with hypoglycemic agents
may have an increased hypoglycemic effect when combined with hypoglycemic agents
may have an increased hypoglycemic effect when combined with hypoglycemic agents
may have an increased QTc-prolonged effect when combined with chloroquine
may have an increased QTc-prolonged effect when combined with chloroquine
may have an increased QTc-prolonged effect when combined with chloroquine
may have an increased QTc-prolonged effect when combined with chloroquine
may have an increased QTc-prolonged effect when combined with chloroquine
Antineoplastic agents will reduce the plasma concentrations of the antibiotics.
when both the drugs are combined, carmustine may decrease the renal secretion of sparfloxacin and increases the serum levels 
when both drugs are combined, there may be a reduced plasma concentration of quinolone antibiotics  
Actions and spectrum:Â
sparfloxacin is a broad-spectrum antibiotic that belongs to the fluoroquinolone class of drugs. It is used to treat various bacterial infections. sparfloxacin works by inhibiting the enzymes involved in DNA replication and repair in bacteria, leading to bacterial cell death.
It is effective against a wide range of Gram-negative and Gram-positive bacteria, including strains that are resistant to other antibiotics. However, it is worth noting that the use of sparfloxacin has become more limited due to safety concerns and potential side effects.Â
Frequency not definedÂ
DiarrhoeaÂ
nauseaÂ
increased of liver enzymesÂ
anaphylactoid reactionÂ
dizzinessÂ
TremorsÂ
rhabdomyolysisÂ
eosinophiliaÂ
abdominal painÂ
vomitingÂ
renal failureÂ
HeadacheÂ
convulsionsÂ
myalgiaÂ
thrombocytopeniaÂ
Black Box Warning:Â
sparfloxacin carries a black box warning due to the risk of potentially severe, even life-threatening, adverse effects. This includes the risk of QT interval prolongation, which can lead to serious heart arrhythmias. Additionally, sparfloxacin may cause tendonitis and tendon rupture, particularly in older adults.Â
Contraindication/Caution:Â
Contraindication:Â
Â
Caution:Â
Â
Comorbidities:Â
Pregnancy consideration: pregnancy category: CÂ
Lactation: excreted into human milk: yes Â
Pregnancy category:Â
Pharmacology:Â
sparfloxacin is a broad-spectrum antibiotic belonging to the fluoroquinolone class. Its pharmacology centers on inhibiting the activity of bacterial DNA gyrase and topoisomerase IV enzymes, crucial for DNA replication, repair, and transcription in bacteria. By interfering with these processes, sparfloxacin disrupts bacterial cell division and replication, leading to cell death. This is effective against a wide range of gram-negative and gram-positive bacteria, making it valuable for treating various infections, including respiratory, urinary tract, and sexually transmitted infections.  Â
Pharmacodynamics:Â
Â
Pharmacokinetics:Â
AbsorptionÂ
sparfloxacin is well-absorbed from the gastrointestinal tract after oral administration. Its bioavailability is 85-95%. Food can affect its absorption, as taking sparfloxacin with food may reduce the rate but not the extent of absorption. Therefore, it is typically recommended to take sparfloxacin on an empty stomach, usually 1-2 hours before or after meals.Â
DistributionÂ
After absorption, sparfloxacin is distributed throughout the body. It has good tissue penetration and can achieve therapeutic concentrations in various tissues and fluids, including the lungs, urinary tract, prostate, and skin. It also crosses the blood-brain barrier, which is important for treating infections in the central nervous system.Â
MetabolismÂ
sparfloxacin undergoes limited metabolism in the liver. The primary metabolic pathway involves dealkylation, resulting in the formation of several metabolites. The cytochrome P450 enzyme system, specifically CYP3A4, plays a role in the metabolism of sparfloxacin. Concurrent use of drugs that induce or inhibit CYP3A4 can potentially affect the pharmacokinetics of sparfloxacin.Â
Elimination and excretionÂ
The elimination of sparfloxacin occurs through renal excretion. 40-50% of an administered dose is excreted unchanged in the urine, indicating that renal clearance is the primary route of elimination. The remaining portion of the drug is eliminated through feces and bile.Â
The elimination half-life of sparfloxacin is 20-25 hours in individuals with normal renal function.Â
Administration:Â
Patient information leafletÂ
Generic Name: sparfloxacinÂ
Pronounced: (spar-flox-a-sin)Â Â
Why do we use sparfloxacin?Â